NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Monday as it is currently trading at $26.78, above its previous 52-week high of $26.76 with 5,629 shares traded as of 9:30 a.m. ET. Average volume has been 747,600 shares over the past 30 days. Myriad has a market cap of $2.21 billion and is part of the services sector and diversified services industry. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter